Incretin|Based Weight Loss Pharmacotherapy

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance ...

This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones ...

Incretin-based therapies for the treatment of obesity-related diseases

Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized ...

Incretin hormone agonists: Current and emerging pharmacotherapy ...

Incretin hormone agonists represent a significant advancement in the pharmacotherapy of obesity, offering substantial weight reduction and cardiometabolic ...

Incretin hormone agonists: Current and emerging pharmacotherapy ...

Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management · Authors · Affiliations.

Keeping the weight off | Nature Medicine

Incretin-based drugs have demonstrated unprecedented efficacy in weight-loss ... pharmacotherapy-meditated weight loss. These new drugs ...

The role of incretin receptor agonists in the treatment of obesity - Forst

In patients experiencing weight regain or insufficient weight loss following metabolic surgery, subcutaneous semaglutide has been shown to ...

A Review of Incretin Therapies Approved and in Late-Stage ...

Newer incretin therapies have demonstrated weight reduction between 15% to 25%, far outpacing non-incretin therapies for weight management.

an update on the available medications and drugs under investigation

Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight ...

Pharmacotherapy for obesity: moving towards efficacy improvement

Semaglutide is a newer anti-obesity medication that changes the overall landscape, as phase 3 studies show a mean weight loss near the 15% ...

Tirzepatide Once Weekly for the Treatment of Obesity

Historically, the treatment of obesity focused almost exclusively on lifestyle-based ... treatment with a medication that promotes weight loss ...

Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond ...

It was first approved in 1959 for short-term use for weight loss based on a 36-week trial that showed both continuous and intermittent administration of ...

Obesity in adults: Drug therapy - UpToDate

- Alternatives to incretin-based therapies · Monitoring · Duration of ... We consider a weight loss medication to be effective if weight loss exceeds ...

Effectiveness of Combining Antiobesity Medication With an ...

Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized ...

Obesity pharmacotherapy: incretin action in the central nervous system

Animal model data suggest that GIP may stimulate further weight loss when coadministered with a GLP-1R agonist by inducing further reduction of food intake, ...

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance ...

Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and ...

Pharmacotherapy for Obesity | JN Learning

Five drugs are now approved by the US FDA for long-term weight management in adults: orlistat, phentermine/topiramate, naltrexone/bupropion extended release, ...

Pharmacotherapy for obesity: What you need to know

Lorcaserin (Belviq) was approved by the FDA in 2012 for chronic weight management. It suppresses appetite by activating the serotonin 2C ...

Review GLP-1 physiology informs the pharmacotherapy of obesity

Nonetheless, preclinical studies examining how GLP1RA such as semaglutide induces weight loss identify a reduction of food intake without changes in locomotion ...

Continued Treatment With Tirzepatide for Maintenance of Weight ...

Lifestyle interventions are a cornerstone of obesity management; however, sustaining weight reduction achieved through lifestyle-based caloric ...

Pharmacotherapy for adults with overweight and obesity - The Lancet

In adults with overweight and obesity, phentermine–topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 ...